Today: 9 June 2026
Browse Category

NASDAQ:PRAX 16 October 2025 - 14 January 2026

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Shares of Praxis Precision Medicines rose about 8% to $303.23 by mid-afternoon Wednesday after the company named epilepsy specialist Dr. Orrin Devinsky as head of clinical strategy. Investors are watching two FDA drug applications set for mid-February. Praxis recently raised $575 million in a public offering. The broader biotech sector outperformed the market, while major indexes fell.
14 January 2026
·
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines shares jumped 13.25% to $304.58 Monday after the FDA granted Breakthrough Therapy Designation to ulixacaltamide for essential tremor. The company plans to file a New Drug Application in early 2026. BTIG raised its price target on PRAX to $843 from $507. The stock slipped about 1% in after-hours trading.
30 December 2025
···
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines shares jumped 13% to $304.58 after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The stock traded between $318.08 and $275.00 during the session. Praxis said it plans to file a New Drug Application in early 2026. Analyst BTIG raised its price target on Praxis to $843.
30 December 2025
··
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines shares traded near $265 on December 9, 2025, up over 500% in three months and close to a 52-week high of $278, giving the company a $6.6 billion market cap. The surge followed positive Phase 3 results for ulixacaltamide in essential tremor, new bullish analyst targets, and increased volatility after a short-seller attack.
9 December 2025
·
Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines shares surged 30.5% to close at $247.99 on December 5, hitting a new 52-week high after positive epilepsy trial results and a favorable FDA pre-NDA meeting. The company’s market cap reached about $6.2 billion. PRAX stock has gained over 500% in three years but remains down 72% over five years. Wall Street sentiment is mostly positive, though some skepticism remains.
6 December 2025
·
Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

Treasure Global (NASDAQ:TGL) surged about 276% on December 5, 2025, after a 1-for-20 reverse stock split and news of an acquisition. SMX (NASDAQ:SMX) jumped 135%, and Wheeler Real Estate Investment Trust (NASDAQ:WHLR) gained 98%. The S&P 500, Nasdaq 100, and Dow all closed higher, but small- and mid-cap stocks saw the largest percentage moves.
6 December 2025
············
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines shares jumped nearly 40% intraday on December 5 after its pivotal epilepsy trial was stopped early for efficacy and the company reported a positive pre-NDA meeting with the FDA for its essential tremor drug. By late morning, PRAX traded around $265–266, hitting a new 52-week high and pushing its market cap above $1.1 billion. The stock is up over 200% year-to-date.
5 December 2025
·
Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines shares traded around $189.97 early December 5 after surging on positive FDA feedback for its essential tremor drug and new data in rare epilepsies. The stock swung between $180.25 and $305.55 intraday, with a market cap near $1.1 billion. PRAX has gained over 1,700% in 12 months, but remains volatile amid short-seller pressure and ongoing losses.
5 December 2025
·
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares soared 183% to $162.71 on Thursday after its drug ulixacaltamide met all key goals in a Phase 3 trial for essential tremor. The results showed significant improvement in patient function and no serious side effects. The company plans to seek FDA approval by early 2026 and launched a public stock offering to fund commercialization.
17 October 2025
·
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis shares soared nearly 180% premarket Oct. 16 after positive Phase 3 results for ulixacaltamide in essential tremor, hitting a new 52-week high. The drug met all primary and secondary endpoints in two trials and showed no serious safety issues. Praxis plans to seek FDA approval by early 2026. The company reported a Q2 net loss of $71.1M but held $446M in cash at mid-2025.
16 October 2025
··

Stock Market Today

  • Corn Futures Close Mixed on Monday Amid Steady Crop Ratings and Export Sales
    June 8, 2026, 8:11 PM EDT. Corn futures saw mixed closing prices Monday, with front-month contracts up to 1 1/4 cents higher and other contracts down up to 1 3/4 cents. The national average cash corn price rose 1 1/2 cents to $3.85 3/4. USDA reported a private export sale of 103,000 metric tons to Japan. U.S. Department of Agriculture data showed 97% of U.S. corn planted and 67% rated good to excellent condition, steady from last week. U.S. corn export inspections increased 9.21% week-on-week to 1.911 million metric tons, up 10.54% year-on-year, led by shipments to Mexico, South Korea, and Spain. Brazil's second crop harvest is 4.4% complete with a slightly lowered forecast of 108.2 million metric tons. July 26 corn futures closed at $4.18 3/4, up 1 1/4 cents.

Latest articles

Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

Broadcom Stock Rebounds, AI Remains an Open Question for Wall Street

9 June 2026
Broadcom shares jumped 2.8% to $396.60 as chip stocks rebounded after last week’s $1 trillion sector wipeout, but investors remain cautious after Broadcom’s Q2 revenue missed expectations and the company declined to raise its 2027 AI revenue forecast, fueling concerns that rapid AI growth may not meet Wall Street’s high demands.
BitMine Stock Gains as Ether Holdings Approach 5% Target

BitMine Stock Gains as Ether Holdings Approach 5% Target

9 June 2026
BitMine Immersion Technologies shares jumped 6% after revealing ether holdings climbed to 5.54 million tokens, now 4.59% of Ethereum’s supply, with $9.6 billion in crypto, cash and stakes. The company priced a $273.8 million preferred stock offering, with proceeds possibly funding more ETH purchases and staking. BitMine projects $230 million in annualized staking revenues but warns of risks if ETH or financing falters.
Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

9 June 2026
Mingteng International shares soared 81.3% to $1.94 after the company ended its at-the-market stock sale plan, having raised about $20.6 million in gross proceeds; trading volume hit 24.2 million, dwarfing its $12 million market value, as the move outpaced gains in other U.S.-listed China auto stocks.
Peso Rebounds, But Mexico’s Next Inflation Print Looms

Peso Rebounds, But Mexico’s Next Inflation Print Looms

9 June 2026
Mexico’s peso edged up 0.09% to 17.4644 per dollar after Iran and Israel paused attacks, but traders turned cautious ahead of Tuesday’s Mexico inflation data, which could shape Banxico rate expectations and impact the peso’s yield advantage that has supported the currency.
Go toTop